Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -20.38%. However, over the past six months, we’ve seen a stronger performance of -41.61%. The price of NRIX leaped by -23.31% over the last 30 days. And in the last five days, it has fallen by -11.97%.
In terms of market performance, Nurix Therapeutics Inc had a fairly even. The highest value for the stock in the past year was $29.56 on 11/11/24, and the lowest value was recorded at $11.20 on 02/28/24.
52-week price history of NRIX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Nurix Therapeutics Inc’s current trading price is -49.26% away from its 52-week high, while its distance from the 52-week low is 33.93%. The stock’s price range during this period has varied between$11.20 and $29.56. The Nurix Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.05 million for the day, a figure considerably higher than their average daily volume of 0.76 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Nurix Therapeutics Inc (NRIX) has experienced a quarterly decline of -31.97% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.14B and boasts a workforce of 286 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 21.28, with a change in price of -6.97. Similarly, Nurix Therapeutics Inc recorded 850,599 in trading volume during the last 100 days, posting a change of -31.73%.
NRIX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NRIX stands at 0.05. Similarly, the long-term debt-to-equity ratio is also 0.04.
NRIX Stock Stochastic Average
Nurix Therapeutics Inc’s raw stochastic average for the past 50 days is presently 0.15%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 0.18%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 12.75% and 13.22%, respectively.
